Resistance Data Across 9 Clinical Trials

Explore the BIKTARVY resistance overview

Long-Term Treatment-Naïve Efficacy Data

Discover BIKTARVY 5-year efficacy data

5-Year Long-Term Safety and Tolerability Profile

Explore BIKTARVY safety data

Learn About These Special Populations

Study 4030: Virologically Suppressed Adults, Including Those With Known or Suspected Preexisting M184V/I Resistance Mutation

Explore the data

Study 5310: Virologically Suppressed Adult Women Who Are Pregnant

View the Prescribing Information to learn more about this population

6 YEARS AS THE #1 PRESCRIBED REGIMEN FOR PEOPLE STARTING AND SWITCHING HIV-1 TREATMENT

Fueled by the power of bictegravir1

SOURCE: IQVIA LAAD, July 2018 through July 2024*

Real conversations logo.

Hear from key opinion leaders, Joel E. Gallant, MD, MPH, and Calvin J. Cohen, MD, MSc, as they discuss the events that shaped the way providers approach HIV treatment. Dr. Cohen is an employee of Gilead. Dr. Gallant is a former employee of Gilead.

See Dr. Joel Gallant and Dr. Calvin Cohen discuss more HIV topics:

*This information is an estimate derived from the use of information under license from the following IQVIA information service: IQVIA LAAD, for the period of July 2018 through July 2024. IQVIA expressly reserves all rights, including rights of copying, distribution, and republication.

Reference: 1. Data on file. Gilead Sciences, Inc.